TransMedics Group (TMDX) Tops Q3 EPS by 30c, provides guidance

TransMedics Group (NASDAQ: TMDX) reported Q3 EPS of $0.66, $0.30 better than the analyst estimate of $0.36. Revenue for the quarter came in at $143.8 million versus the consensus estimate of $144.59 million.

GUIDANCE:

TransMedics Group sees FY2025 revenue of $595-605 million, versus the consensus of $600.4 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
• Western Midstream prices $700M in senior notes due 2036
• Taysha Gene Therapies (TSHA) PT Raised to $11 at Citizens on REVEAL Data Update